Adbiotech

애드바이오텍 · 179530

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$35.1M (₩48.4B)

Overview

Adbiotech develops antibody-based biological products designed to prevent and treat diseases in livestock, aquaculture, and humans, offering alternatives to conventional vaccines and antibiotics.

Its products target farmers, aquaculture operators, and the broader animal-health supply chain. Listed on KOSDAQ, Korea's tech and small-cap board, the company's core platform is IgY technology, which extracts disease-fighting antibodies from egg yolk to create natural passive-immune preparations against viruses, bacteria, and parasites.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$9.3M

▲ +15.8% YoY

Operating profit · FY2025

−US$2.5M

Loss narrowed

Net income · FY2025

−US$2.4M

Loss narrowed

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$7.6M(₩10.5B)	US$8.1M(₩11.1B)	US$9.3M(₩12.9B)
Operating profit	−US$3.5M(−₩4.8B)	−US$3M(−₩4.1B)	−US$2.5M(−₩3.5B)
Net income	−US$3.9M(−₩5.4B)	−US$6.5M(−₩9B)	−US$2.4M(−₩3.3B)

Revenue

FY2023US$7.6M
FY2024US$8.1M
FY2025US$9.3M

Operating profit

FY2023−US$3.5M
FY2024−US$3M
FY2025−US$2.5M

Net income

FY2023−US$3.9M
FY2024−US$6.5M
FY2025−US$2.4M

Key ratios (FY2025)

ROE

-24.6%

Debt/Eq

257.5%

Op. margin

-27.1%

Net margin

-25.8%

Rev. YoY

▲ +15.8%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?